GILD

에 대한 최신 뉴스 Gilead Sciences (NASDAQ:GILD) 주식

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Analyst Color

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Analyst Ratings

Movers

Trading Ideas

General

ACLX

길리어드 사이언스(NASDAQ:GILD)의 주식은 수요일 7% 이상 상승 마감했다. 이는 화요일 회사가 2024년 4분기 조정 EPS가 1.90달러로, 컨센서스 1.70달러를 초과했다고 보고한 이후의 일이다.

길리어드, 2025년 전망 상향 조정 및 HIV 예방을 위한 레나카파비르 출시 목표

After-Hours Center

길리어드 사이언스(NASDAQ:GILD)는 화요일(12일) 장 마감 후 4분기 재무 실적을 발표했다. 다음은 보고서의 주요 내용이다.

길리어드 사이언스, 4분기 실적 발표 이후 시간외 거래 4% 상승

Long Ideas

Pre-Market Outlook

Markets

AVGO

NVDA

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 개선되었음을 보여 주었다. 지수는 월요일(10일)에 &#34;중립&#34; 구역으로 이동했다.

엔비디아·브로드컴 급등 속 나스닥 1% 상승: 투자 심리 호전, 공포·탐욕 지수는 &#39;중립&#39; 영역으로

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

– Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area –
– First and Only Treatment That Achieved Statistically Significant Improvements Across Biochemical Response, Alkaline Phosphatase Normalization, and Pruritus Versus Placebo –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment option for people living with the rare liver disease in the European Economic Area (EEA).

Global

Gilead Sciences Announces European Commission Approval Of Seladelpar For Rare Liver Disease Primary Biliary Cholangitis In European Economic Area

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has fallen 8.91% since its last report. The company recently reported that it has 22.93 million shares sold short, which is 1.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739980821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Gilead Sciences?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$77.50</td>
<td>$27.5K</td>
<td>206</td>
<td>6.0K</td>
</tr>
<tr>
<td>EYPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.00</td>
<td>$49.7K</td>
<td>431</td>
<td>1.0K</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$100.00</td>
<td>$37.1K</td>
<td>475</td>
<td>384</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$108.00</td>
<td>$38.3K</td>
<td>45</td>
<td>339</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$162.5K</td>
<td>3.5K</td>
<td>222</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$110.4K</td>
<td>5.0K</td>
<td>183</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$240.00</td>
<td>$28.4K</td>
<td>5</td>
<td>136</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$257.3K</td>
<td>1.3K</td>
<td>134</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$200.00</td>
<td>$106.5K</td>
<td>203</td>
<td>95</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$550.00</td>
<td>$171.4K</td>
<td>710</td>
<td>66</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 62 contract(s) at a $77.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.5K, with a price of $445.0 per contract. There were 206 open contracts at this strike prior to today, and today 6063 contract(s) were bought and sold. 
• For EYPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>), we notice a put option sweep that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $5.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $49.7K, with a price of $95.0 per contract. There were 431 open contracts at this strike prior to today, and today 1002 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a call option sweep that happens to be bearish, expiring in 304 day(s) on December 19, 2025. This event was a transfer of 24 contract(s) at a $100.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $37.1K, with a price of $1553.0 per contract. There were 475 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on March 7, 2025. This event was a transfer of 276 contract(s) at a $108.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $38.3K, with a price of $139.0 per contract. There were 45 open contracts at this strike prior to today, and today 339 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $162.5K, with a price of $3250.0 per contract. There were 3527 open contracts at this strike prior to today, and today 222 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 96 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $110.4K, with a price of $1150.0 per contract. There were 5079 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• Regarding WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 16 contract(s) at a $240.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.4K, with a price of $1780.0 per contract. There were 5 open contracts at this strike prior to today, and today 136 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option sweep with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 83 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $257.3K, with a price of $3100.0 per contract. There were 1316 open contracts at this strike prior to today, and today 134 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 82 contract(s) at a $200.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1300.0 per contract. There were 203 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 40 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $171.4K, with a price of $4285.0 per contract. There were 710 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

EYPT

TMDX

10 Health Care Stocks Whale Activity In Today's Session

16 analysts have shared their evaluations of Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Gilead Sciences, revealing an average target of $104.38, a high estimate of $123.00, and a low estimate of $80.00. This current average reflects an increase of 12.88% from the previous average price target of $92.47. 
<img src="https://www.benzinga.com/files/images/story/2025/1739887260_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Gilead Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$96.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Matthew Biegler</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$109.00</td>
<td>-</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$96.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Gilead Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Gilead Sciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Gilead Sciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>Unveiling the Story Behind Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Gilead Sciences's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Gilead Sciences displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.02%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.32% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 1.26, Gilead Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

16 Analysts Have This To Say About Gilead Sciences

Gilead Sciences Announces FDA Acceptance Of NDA For Lenacapavir For HIV Prevention Under Priority Review With PDUFA Date Set For June 19, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst David Katz upgraded the rating for Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) from Hold to Buy and raised the price target from $105 to $118. Wynn Resorts shares closed at $88.82 on Friday. <a href="https://www.benzinga.com/quote/wynn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>CIBC analyst Mark Jarvi upgraded TransAlta Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAC#NYSE">TAC</a>) from Neutral to Outperformer and lowered the price target from C$23 to C$19.5. TransAlta shares closed at $10.53 on Friday. <a href="https://www.benzinga.com/quote/TAC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Boss upgraded the rating for Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from Neutral to Overweight and boosted the price target from $41 to $47. Bath &amp; Body Works shares closed at $36.47 on Friday. <a href="https://www.benzinga.com/quote/BBWI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Maher Yaghi upgraded Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) from Sector Perform to Sector Outperform and announced a $208 price target. Digital Realty Trust shares closed at $164.28 on Friday. <a href="https://www.benzinga.com/quote/DLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst James Shin upgraded Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Hold to Buy and raised the price target from $80 to $120. Gilead shares closed at $104.08 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BBWI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18065553/image-152-1024x503.png" alt="" class="wp-image-786637" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18065553/image-152-1024x503.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18065553/image-152-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18065553/image-152-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18065553/image-152.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>

Upgrades

BBWI

CRSP

WYNN

This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Deutsche Bank analyst James Shin upgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Hold to Buy and raises the price target from $80 to $120.

Price Target

Deutsche Bank Upgrades Gilead Sciences to Buy, Raises Price Target to $120

<ul>
<li>Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in MTAP-deletion NSCLC</li>
<li>The potential first-in-class clinical combination of IDE397 and Trodelvy targets two mechanistically distinct and complementary nodes of MTAP-deletion in solid tumors</li>
<li>MTAP-deletion prevalence in NSCLC is estimated to be approximately 15%</li>
</ul>

Contracts

IDYA

IDEAYA Biosciences Announced An Additional Clinical Study Collaboration And Supply Agreement With Gilead Sciences To Evaluate IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan) For Methylthioadenosine Phosphorylase-Deletion Non-Small Cell Lung Cancer

Tuesday, Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) reported fourth-quarter 2024 adjusted EPS of $1.90, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $1.70</a>.
Sales increased 6% year over year to $7.57 billion, beating the consensus of $7.14 billion. This was primarily due to higher sales in the HIV segment, as well as in Oncology and Liver Disease. Sales were partially offset by lower <a href="https://www.benzinga.com/pressreleases/25/02/b43639858/gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">sales of Veklury (remdesivir)</a>.
HIV sales increased 16% to $5.45 billion, <a target="_blank" href="https://s29.q4cdn.com/585078350/files/doc_financials/2024/q4/GILD-Q424-Summary-of-Prepared-Remarks-11-February-2025.pdf" rel="noreferrer noopener">driven</a> by demand, higher realized price, and favorable inventory dynamics.
Biktarvy sales for the quarter increased from $3.12 billion to $3.8 billion.
Liver disease sales increased 4% to $719 million, driven by a strong Livdelzi launch and increased HBV/HDV demand, partially offset by lower HCV sales from fewer patient starts.
Dividend: Gilead Sciences increased its quarterly cash dividend by 2.6% <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640030/gilead-sciences-announces-2-6-percent-increase-in-first-quarter-2025-dividend" rel="noreferrer noopener">to $0.79 per share</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing</a>
Guidance: Gilead expects 2025 adjusted EPS of $7.70-$8.10 versus the consensus of $7.58 and sales of $28.2 billion—$28.6 billion versus the consensus of $28.42 billion.
&#8220;From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025, with its unique opportunity to extend the reach of HIV prevention,&#8221; said Daniel O'Day, Gilead's Chairman and CEO.
Piper Sandler raised Gilead&#8217;s price forecast from $105 to $110, with an <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noreferrer noopener">unchanged Overweight rating</a>. The analysts cited the upcoming commercial launch of lenacapavir in PrEP later this year and several notable late-stage readouts on tap.
After filing for regulatory approval of lenacapavir for PrEP last year, Gilead still expects a potential commercial launch in 2025. This could help the company secure its place in the PrEP market and improve patient adherence. It will also strengthen its HIV leadership into the late 2030s.
Goldman Sachs writes that Gilead is well-positioned for the lenacapavir launch.
On the HIV business, Goldman Sachs analyst Salveen Richter says commentary was largely consistent with the recent investor event.
The analyst sees challenges in oncology due to competition affecting Kite and Trodelvy but remains positive on Arcellx Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) partnered therapy, anito-cel, for multiple myeloma and is keeping an eye on Trodelvy&#8217;s expansion.
Needham analyst Joseph Stringer sees two key events driving value in 2025: the anticipated launch of lenacapavir for HIV prevention and Phase 3 trial updates for Trodelvy in first-line metastatic triple-negative breast cancer.
The analyst maintains a Hold rating on Gilead, citing a balanced risk/reward at current levels. However, Needham is growing more optimistic about the stock. The analysts credit the strong performance of Gilead's HIV business, improving profit margins, and lenacapavir's potential to boost revenue.
Price Action: Gilead Sciences stock is up 7.73% at $103.57 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43665455/te-connectivity-snaps-up-richards-manufacturing-for-2-3-billion-details" target="_blank" rel="noreferrer noopener">TE Connectivity Snaps Up Richards Manufacturing For $2.3 Billion: Details</a></li>
</ul>
Image via Gilead Sciences

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by <a href="https://www.benzinga.com/government/regulations/25/02/43656846/inflation-rises-more-than-expected-in-january-chills-interest-rate-cut-hopes">midday trading in New York.</a>
The S&amp;P 500 was down 0.2%, while the Nasdaq 100 was flat, both rebounding from sharp declines following the January Consumer Price Index report. Small-cap stocks underperformed, with the Russell 2000 slipping 0.8%.
The headline CPI rose 3% year over year in January, surpassing both December's 2.9% reading and economist forecasts of 2.9%. On a monthly basis, inflation increased 0.5%, outpacing expectations of 0.3% and accelerating from December's 0.4% gain. This marked the fastest monthly inflation rate since August 2023.
Core inflation, which excludes food and energy, climbed to 3.3% year over year from 3.2% in December. On a monthly basis, core CPI increased 0.4%, exceeding estimates of 0.3% and doubling December's 0.2% rise.
Treasuries and interest rate markets reacted sharply to the inflation data. Traders scaled back expectations for Federal Reserve rate cuts, now projecting only one reduction by December 2025.
Treasury yields surged, reflecting heightened investor uncertainty. The 10-year Treasury yield jumped 10 basis points to 4.64%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 1%.
Despite rising Treasury yields and a stronger dollar, gold edged up 0.2% to $2,910 per ounce. Oil prices dropped 2% after reports that Donald Trump spoke with Russian President Vladimir Putin, fueling speculation about a potential ceasefire in Ukraine.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also rebounded from earlier session losses.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,688.40</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,056.85</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,411.00</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.59</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.2% down to $603.77.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.4% down to $444.41.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;flattened at $528.09.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.8% to $224.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.4%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.2%.</li>
</ul>
Wednesday&#8217;s Stock Movers
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped more than 4% after the electric vehicle maker tumbled 6.3% on Tuesday, reaching oversold levels and extending its losing streak to five consecutive sessions.</li>
</ul>
Stocks reacting to company earnings reports included: 
<ul>
<li>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 15.7%</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): up 4.5%</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 5.6%</li>
<li>América Móvil, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>): down 1.4%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>): up 0.2%</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>): up 0.3%</li>
<li>Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>): up 2.9%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): up 6.8%</li>
<li>Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>): down 10.2%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): up 2.2%</li>
<li>Chimera Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>): down 8.9%</li>
<li>Ryder System Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>): up 4.0%</li>
<li>Smurfit WestRock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>): down 5.8%</li>
<li>Sonic Automotive Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>): down 2.4%</li>
<li>Alkermes Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>): up 4.1%</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>): up 1.0%</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>): down 4.6%</li>
<li>Blackstone Mortgage Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXMT#NYSE">BXMT</a>): up 2.8%</li>
<li>Camtek Ltd/Israel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>): up 1.5%</li>
<li>Chefs' Warehouse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>): up 13.0%</li>
<li>Diebold Nixdorf Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>): down 3.2%</li>
<li>Dominion Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.6%</li>
<li>Exelon Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): up 0.4%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43663963/record-high-egg-prices-drive-inflation-higher-in-january">Record-High Egg Prices Drive Inflation Higher In January</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

ALKS

AVXL

BIIB

BXMT

CAMT

CHEF

SPDR Dow Jones Industrial Average ETF Trust

SCCO

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Sector Perform and raises the price target from $84 to $90.

RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $90

Goldman Sachs analyst Salveen Richter maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and raises the price target from $85 to $96.

Goldman Sachs Maintains Neutral on Gilead Sciences, Raises Price Target to $96

BMO Capital analyst Evan Seigerman maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $110 to $115.

BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $115

Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $105 to $120.

Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $120

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday.
Shares of Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS <a href="https://in.benzinga.com/general/health-care/25/02/43643001/gilead-sciences-shares-push-higher-after-q4-report-heres-why">guidance above estimates</a>.
Gilead Sciences reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.70. Quarterly revenue came in at $7.56 billion which beat the analyst consensus estimate of $7.13 billion and is an increase over revenue of $7.11 billion from the same period last year.
Gilead Sciences shares jumped 8.1% to $103.88 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) shares jumped 30.7% to $88.07 after the company reported better-than-expected fourth-quarter financial results and issued FY25 revenue guidance above estimates. Multiple analysts upgraded the stock following the report.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) rose 19.6% to $14.82 after the company announced statistically significant week 12 data from the Phase 2b trial of rosnilimab in moderate-to-severe rheumatoid arthritis.</li>
<li>Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) gained 17.4% to $58.80 after the company reported quarterly financial results. Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $70 to $80.</li>
<li>EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) rose 16.5% to $24.13.</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) gained 15.5% to $34.78 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Angi Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) surged 15% to $1.9850 following better-than-expected fourth-quarter sales and a year-over-year increase in EPS results.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) climbed 14.6% to $63.05 after the company reported quarterly earnings and revenue above estimates.</li>
<li>Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) gained 13.3% to $18.00.</li>
<li>The Chefs&#8217; Warehouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) gained 11.3% to $60.69 following better-than-expected quarterly reported financial results.</li>
<li>Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) surged 9.2% to $28.05 following a fourth-quarter adjusted EPS and revenue beat.</li>
<li>iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) gained 9.2% to $2.50.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) rose 8.5% to $10.82.</li>
<li>CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) gained 8.4% to $42.95  after the company reported better-than-expected quarterly financial results and Barclays raised its price target on the stock from $55 to $56.</li>
<li>Prudential plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUK#NYSE">PUK</a>) gained 6.1% to $18.10.</li>
<li>IAC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) surged 5.6% to $43.31 following strong quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43658834/this-ppg-industries-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-wednesday">This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday</a></li>
</ul>

Intraday Update

ANAB

ANGI

CFLT

CLMT

UPST

VNET

Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday

Piper Sandler analyst Joseph Catanzaro maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $105 to $110.

Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $110

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $113 to $123.

Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $123

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Gilead Sciencesto Hold

WIIM

Gilead Sciences shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 adjusted EPS guidance above estimates.

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/b43639858/gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results">highlights from the report.&nbsp;</a>
The Details:&nbsp;Gilead Sciences reported quarterly earnings of&nbsp;$1.90&nbsp;per share which beat the analyst consensus estimate of&nbsp;$1.70.&nbsp;Quarterly revenue came in at $7.56 billion&nbsp;which beat the analyst consensus estimate of&nbsp;$7.13 billion&nbsp;and is an&nbsp;increase over revenue of&nbsp;$7.11 billion&nbsp;from the same period last year.
<ul>
<li>Total fourth quarter 2024 product sales increased 7% to $7.5 billion compared to the same period in 2023. </li>
<li>Total product sales excluding Veklury increased 13% to $7.2 billion compared to the same period in 2023, primarily due to higher sales in HIV, as well as in Oncology and Liver Disease.</li>
<li>Non-GAAP product gross margin was 86.7% in the fourth quarter of 2024 compared to 86.1% in the same period in 2023.</li>
<li>Research and development expenses were $1.6 billion in the fourth quarter of 2024 compared to $1.4 billion in the same period in 2023, primarily due to incremental investments and clinical activities across the portfolio.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/25/02/43474797/amazon-faces-trumps-tariffs">Amazon &#8216;Relatively Well-Positioned&#8217; To Face Trump&#8217;s Tariffs: Analyst</a>&nbsp;
&#8220;Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth quarter,&#8221; said Daniel O&#8217;Day, Gilead&#8217;s CEO.
&#8220;From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025, with its unique opportunity to extend the reach of HIV prevention. This potential in HIV, along with our strong and diverse portfolio, and improved operational efficiencies, positions Gilead to deliver increasing patient impact and compelling shareholder returns in the years ahead,&#8221; O&#8217;Day added. 
Outlook:&nbsp;The company sees fiscal 2025 adjusted earnings in a range of&nbsp;$7.70 to $8.10&nbsp;per share, versus the $7.58&nbsp;estimate, and revenue in a range of $28.2 billion to $28.6 billion, versus the&nbsp;$28.42 billion estimate. 
GILD Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Gilead Sciences shares are up 4.42% after hours at $100.39 Tuesday.&nbsp;&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a></li>
</ul>
Image: Shutterstock

Gilead Sciences Shares Push Higher After Q4 Report: Here's Why

Press Releases

Gilead Sciences to Present at Upcoming Investor Conference

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications

Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend

U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

CTSH

ONCY

TSX:ONC

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Deutsche Bank

RBC Capital

Goldman Sachs

BMO Capital

Wells Fargo

길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)의 주식은 수요일 7% 이상 상승 마감했다. 이는 화요일 회사가 2024년 4분기 조정 EPS가 1.90달러로, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">컨센서스 1.70달러를 초과</a>했다고 보고한 이후의 일이다.
매출은 작년 대비 6% 증가한 75.7억 달러로, 컨센서스인 71.4억 달러를 초과했다. 이는 주로 HIV 부문, 종양학 및 간질환 부문의 매출 증가로 인한 것이며, 베클루리(Veklury) (렘데시비르) 매출 감소로 일부 상쇄되었다.
HIV 매출은 16% 증가하여 54.5억 달러에 달했으며, <a href="https://s29.q4cdn.com/585078350/files/doc_financials/2024/q4/GILD-Q424-Summary-of-Prepared-Remarks-11-February-2025.pdf" target="_blank" rel="noreferrer noopener">수요 증가, 더 높은 실현 가격 및 재고 동향의 긍정적 영향</a>이 주요 원인이었다.
빅타비(Biktarvy)의 분기 매출은 31.2억 달러에서 38억 달러로 증가했다.
간질환 매출은 7.19억 달러로 4% 증가했으며, 이는 리브델지(Livdelzi)의 강력한 출시와 HBV/HDV 수요 증가에 기인한 것이지만, 환자 시작 감소로 인한 HCV 매출 감소가 일부 상쇄되었다.
배당금: 길리어드 사이언스는 분기 현금 배당금을 2.6% 인상하여 <a href="https://www.benzinga.com/pressreleases/25/02/b43640030/gilead-sciences-announces-2-6-percent-increase-in-first-quarter-2025-dividend" target="_blank" rel="noreferrer noopener">0.79달러로</a> 발표했다.
또한 읽어보기: <a href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" target="_blank" rel="noreferrer noopener">길리어드, 덜 빈번한 예방 접종 희망을 제공하는 새로운 연간 HIV 주사제 발표</a>
가이던스: 길리어드은 2025년 조정 EPS를 7.70달러-8.10달러로 예상하며, 컨센서스는 7.58달러이다. 매출은 28.2억 달러-28.6억 달러로 예상하며, 이는 컨센서스 28.42억 달러를 상회한다.
&#8220;상업적 강점을 바탕으로, 우리는 2025년 여름에 HIV PrEP용 레나카파비르(lenacapavir)의 잠재적 출시를 계획하고 있다. 이는 HIV 예방 범위를 확장할 수 있는 독특한 기회를 제공한다&#8221; 고 길리어드의 회장 겸 CEO인 다니엘 오데이(Daniel O&#8217;Day)가 말했다.
파이퍼 샌들러는 길리어드의 목표 주가를 105달러에서 110달러로 상향 조정했으며, <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noreferrer noopener">비중 확대 등급은 변동 없음</a>을 유지했다. 분석가들은 올해 말 PrEP에서 레나카파비르의 상업적 출시와 몇 가지 중요한 후기 단계 결과 발표를 인용했다.
길리어드은 작년에 레나카파비르의 PrEP에 대한 규제 승인 신청서를 제출한 후, 여전히 2025년 상업적 출시 가능성을 기대하고 있다. 이는 회사가 PrEP 시장에서의 입지를 확보하고 환자 순응도를 개선하는 데 도움이 될 수 있다. 또한 2030년대 후반까지 HIV 리더십을 강화할 것이다.
골드만삭스는 길리어드이 레나카파비르 출시를 잘 준비하고 있다고 언급했다.
HIV 사업에 대해 골드만삭스의 애널리스트인 살빈 리히터(Salveen Richter)는 코멘트가 최근 투자자 행사와 대체로 일치했다고 전했다.
분석가는 카이트(Kite)와 트로델비(Trodelvy)에 영향을 미치는 경쟁으로 인해 종양학에서 어려움이 있다고 보지만, 아셀엑스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>)의 파트너십 치료제인 아니토셀(anito-cel)에 대한 긍정적인 전망을 유지하고, 트로델비의 확장을 주목하고 있다.
니덤의 애널리스트인 조셉 스트링거(Joseph Stringer)는 2025년에 가치를 주도할 두 가지 주요 이벤트가 있다고 보고한다: HIV 예방을 위한 레나카파비르의 출시 예상과 1차 전이성 삼중음성 유방암에 대한 트로델비의 3상 시험 업데이트이다.
애널리스트는 현재 수준에서 균형 잡힌 위험/보상으로 인해 길리어드에 대한 보유 등급을 유지하지만, 길리어드의 HIV 사업의 강력한 성과, 개선된 이익률, 레나카파비르의 매출 증가 잠재력에 대해 점점 더 낙관적으로 보고 있다.
가격 동향: 길리어드 사이언스의 주식은 수요일 7.46% 상승한 103.31달러에 마감되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43665455/te-connectivity-snaps-up-richards-manufacturing-for-2-3-billion-details" target="_blank" rel="noreferrer noopener">TE 커넥티비티, 리차드 제조사를 23억 달러에 인수</a></li>
</ul>
이미지 출처: Gilead Sciences
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 화요일(12일) 장 마감 후 4분기 재무 실적을 발표했다. 다음은 보고서의 <a href="https://www.benzinga.com/pressreleases/25/02/b43639858/gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noopener">주요 내용이다.</a>
실적 세부 사항: 길리어드 사이언스는 애널리스트 컨센서스 예상치 1.70달러를 상회하는 주당 1.90달러의 분기 순이익을 발표했다. 분기 매출은 75억 6,000만 달러로 애널리스트 컨센서스 예상치 71억 3,000만 달러를 상회했으며 전년 동기 71억 1,000만 달러의 매출보다 증가했다.
<ul>
<li>2024년 4분기 총 제품 매출은 2023년 같은 기간에 비해 7% 증가한 75억 달러를 기록했다.</li>
<li>베클루리(Veklury)를 제외한 총 제품 매출은 2023년 같은 기간에 비해 13% 증가한 72억 달러로, 주로 HIV와 종양학 및 간 질환 분야의 매출 증가에 힘입어 증가했다.</li>
<li>2024년 4분기 비일반회계기준 제품 매출총이익률은 2023년 같은 기간의 86.1%에 비해 86.7%를 기록했다.</li>
<li>2024년 4분기 연구개발 비용은 2023년 같은 기간의 14억 달러에 비해 16억 달러로, 주로 포트폴리오 전반에 걸친 투자 및 임상 활동의 증가로 인해 증가했다.</li>
</ul>
대니얼 오데이(Daniel O&#8217;Day) CEO는 "길리어드는 2024년에 8%, 4분기에 전년 동기 대비 13%의 기본 비즈니스 제품 매출 성장을 기록하며 또 한 번 매우 강력한 연간 및 4분기 실적을 달성했다&#8221;고 말했다.
"이러한 상업적 강점을 바탕으로 2025년 여름에 HIV 예방 범위를 확장할 수 있는 특별한 기회와 함께 HIV PrEP용 레나카파비르(lenacapavir)의 출시를 계획하고 있다. 길리어드는 강력하고 다양한 포트폴리오, 개선된 운영 효율성과 함께 이러한 HIV 분야의 잠재력을 바탕으로 향후 몇 년 동안 환자들에게 더 많은 영향을 미치고 주주들에게 매력적인 수익을 제공할 수 있을 것으로 기대한다.&#8221;
전망: 길리어드는 2025회계연도 조정 주당순이익을 7.70~8.10달러로 예상하며 추정치 7.58달러보다 높았고, 매출은 282억~286억 달러로 예상해 추정치에 부합했다.
GILD 주가 움직임: <a href=""https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"">Benzinga Pro</a> 데이터에 따르면 길리어드 사이언스 주가는 화요일 애프터마켓에서 4.26% 상승한 100.24달러에 거래되고 있다.
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 개선되었음을 보여 주었다. 지수는 월요일(10일)에 &#8220;중립&#8221; 구역으로 이동했다.
미국 증시는 월요일 상승 마감했으며, 특히 투자자들이 도널드 트럼프 대통령의 관세 위협을 일축하면서 나스닥 종합지수는 약 1% 상승했다. 칩 제조사들의 주가가 상승했는데 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 2.9% 상승, 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) 4.5% 상승, 마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) 3.9% 상승을 나타냈다.
한편, 지난주 미국 증시는 인플레이션과 무역 관세에 대한 우려가 재발하면서 위험 선호도가 줄어들어 하락을 기록했다.
온 세미컨덕터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) 주가는 회사가 부진한 분기 실적을 발표한 후 8% 이상 하락했다. 맥도날드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) 주가는 4분기 실적 발표 후 약 5% 상승했다.
경제지표 측면에서, 미국 소비자 인플레이션 기대치가 1월에 3%로 세 번째 연속적으로 안정세를 보였다.
S&amp;P 500 지수 대부분의 섹터는 상승 마감하였으며, 에너지, 정보기술, 공공서비스 섹터가 상승했다. 그러나 금융과 유틸리티 섹터는 전체 시장 추세와 반대로 하락 마감했다.
다우존스는 월요일에 약 167포인트 상승하여 44,470.41포인트로 마감했고, S&amp;P 500은 0.67% 상승하여 6,066.44포인트, 나스닥 종합은 0.98% 상승하여 19,714.27포인트로 마감했다.
오늘 투자자들은 코카콜라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), 메리어트 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), 길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 46.2로 월요일에 &#8220;중립&#8221; 구역으로 이동했다. 이전 지수는 38.8이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

엔비디아·브로드컴 급등 속 나스닥 1% 상승: 투자 심리 호전, 공포·탐욕 지수는 '중립' 영역으로

화요일(11일) 아침 미국 주식 선물이 하락하고 있는 가운데, 투자자들의 주목을 받을 만한 몇 가지 주식은 다음과 같다.
<ul>
<li>코카콜라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 오늘 개장 전 실적을 발표할 예정이며, 주당순이익 52센트, 매출 106억 8천만 달러가 예상된다. 주식은 애프터 마켓에서 0.1% 상승한 64.63 달러에 거래되었다.</li>
<li>하모닉(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>): 4분기 실적이 예상보다 좋았으나, 1분기 가이던스는 부진하다고 발표했다. 1분기 조정 주당순이익을 2~8센트로 예상되며, 이는 14센트의 예상치에 미치지 못한다. 매출은 1억 2천만~1억 3천 5백만 달러로 예상되며, 이는 1억 5천 4백 76만 달러의 예상치보다 낮다. 주식은 애프터마켓에서 29% 하락한 7.90달러에 거래되었다.</li>
<li>메리어트 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>): 오늘 개장 전 실적을 발표할 예정이며 분기 주당순이익이 2.38달러, 매출이 63억 8천만 달러로 예상된다. 주식은 애프터마켓이서  0.3% 하락한 303.51달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하세요.
<ul>
<li>아스테라 랩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>): 4분기 긍정적인 재무 결과를 발표했다. 회사는 1분기 매출을 1억 5천 1백만~1억 5천 5백만 달러로 예상하며, 이는 1억 3천 4백 25만 달러의 예상치보다 높다. 또한 1분기 조정 주당순이익을 28~29센트로 예상한다. 주식은 애프터마켓에서 3.8% 하락한 99.37달러로 거래 되었다.</li>
<li>길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): 애널리스트들은 길리어드의 분기별 주당순이익을 1.70달러, 매출을 71억 4천만 달러로 예상한다. 주식은 애프터마켓에서 0.1% 상승한 95.60달러에 거래되었다.</li>
</ul>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ALAB

HLIT

화요일 주목해야 할 주식: 코카콜라, 메리어트, 하모닉, 아스테라 및 길리어드 사이언스

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ABBV

ELAN

IDXX

PRGO

REGN

TEVA

VTRS

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

머크 앤드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 길리어드 사이언스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>)는 주가가 <a href="https://www.benzinga.com/general/health-care">상당히 다른 양상</a>을 보이는 두 제약 대기업이다.
뉴저지주 라웨이에 본사를 둔 머크는 방금 데스 크로스(Death Cross)를 표시하여 앞으로 발생할 수 있는 문제를 예고했다. 반면 캘리포니아주 포스터 시티에 본사를 둔 길리어드는 강세 모멘텀의 신호인 골든 크로스(Golden Cross)를 보여주고 있다.
<h2 class="wp-block-heading">머크: 불안한 상황</h2>
다양한 의약품과 백신 라인업으로 유명한 머크의 주가가 흔들리고 있다. 지난 1년간 8.72%의 괜찮은 상승세에도 불구하고 최근의 기술적 신호는 좋지 않은 모습을 보이고 있다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-527666" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135243/Screenshot-2024-09-03-at-6.05.48-PM.png" sizes="(max-width: 639px) 100vw, 639px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135243/Screenshot-2024-09-03-at-6.05.48-PM.png 639w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135243/Screenshot-2024-09-03-at-6.05.48-PM-300x214.png 300w" alt="" width="639" height="456" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
우려스러운 데스 크로스—50일 이동 평균선이 200일 이동 평균선을 하향 돌파하는 경우—가 발생하여 약세 추세를 암시하고 있다. 이동평균수렴발산(MACD)가 -0.81로 부정적이고, 상대강도지수(RSI)가 53.93로 과매수 영역에 접어들고 있어 머크는 더 이상 강력한 제약 포트폴리오만으로는 추가 하락을 피하기 어려운 상황이다.
추가 읽기: <a href="https://www.benzinga.com/general/biotech/24/08/40627374/merck-pulls-plug-on-two-keytruda-late-stage-studies-on-underwhelming-data">머크, 두 개의 키트루다 후기 연구 중단 발표</a>
<h2 class="wp-block-heading">길리어드: 골든 웨이브를 타고 상승 중</h2>
반면에 길리어드 사이언스는 상승하고 있다. HIV 및 간염 치료제로 유명한 이 회사는 골든 크로스(Golden Cross)를 경험하고 있으며, 이는 추가 상승 가능성을 암시하는 강세 신호이다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-527668" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135357/Screenshot-2024-09-03-at-6.06.11-PM.png" sizes="(max-width: 639px) 100vw, 639px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135357/Screenshot-2024-09-03-at-6.06.11-PM.png 639w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135357/Screenshot-2024-09-03-at-6.06.11-PM-300x214.png 300w" alt="" width="639" height="456" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
지난달에만 6.82% 상승한 길리어드의 주가는 주요 이동 평균을 훨씬 웃돌았다. MACD는 건강한 1.48, RSI는 68.78로 주가는 강세를 보이고 있지만 투자자들은 과매수 조짐을 주의해야 한다.
<h2 class="wp-block-heading">누가 이길까?</h2>
머크가 약세 추세를 보이는 반면, 길리어드는 상승세를 타고 있다. 투자자들은 이 두 회사의 기술적 신호가 어떻게 다르게 나타나는지를 면밀히 주시할 필요가 있다.
현재로서는 길리어드가 승리한 것으로 보이며, 머크는 주가 회복을 위한 더 강력한 조치가 필요할 것 같다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40419924/gileads-ongoing-battle-against-counterfeit-hiv-medications-persists-with-new-lawsuit-seizes-750k-">길리어드의 가짜 HIV 약물 단속을 위한 지속적인 전투</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Technicals

Signals

머크의 데스 크로스 vs 길리어드의 골든 크로스: 서로 다른 양상을 보이는 두 제약 기업

나스닥 100 지수는 목요일 또 다른 하락세를 보이며 변동성이 심한 세션 이후 6월 초 이후 최저 수준으로 마감했다. 전날 나스닥 100 지수는 3.7% 하락해 <a href="https://www.benzinga.com/markets/equities/24/07/39943580/nasdaq-100-notches-worst-session-since-late-2022-falls-below-key-50-day-moving-average-is-the-ai" target="_blank" rel="noopener" data-google-interstitial="false">2022</a>년 10월 이후 최악의 하락세를 기록했다.
예상보다 높은 2분기 GDP 성장률과 감소하는 물가 압력으로 인해 주식과 위험 자산이 잠시 상승하며 나스닥 100 지수가 뉴욕 정오 거래 중 0.9% 상승했지만, 오후 거래에서는 트레이더들이 연방준비제도(연준)의 금리 인하 베팅을 약간 줄이면서 시장 분위기가 변했다.
오픈AI가 <a href="https://www.benzinga.com/news/24/07/39968522/alphabet-stock-falls-as-openai-plans-searchgpt-what-investors-need-to-know" target="_blank" rel="noopener" data-google-interstitial="false">특정 사용자 그룹</a>에 새로운 검색 기능을 도입하면서 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)은 하락했다.
지난 두 세션 동안 Invesco QQQ Trust(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/qqq" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for QQQ" data-google-interstitial="false">QQQ</a>)가 추적하는 나스닥 100 지수는 4.7% 하락하여 2022년 9월 이후 최악의 이틀 하락세를 기록했다.
<h3 class="wp-block-heading">차트: 나스닥 100 지수는 2022년 9월 이후 최악의 2일 하락세</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-457894" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-1024x487.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-1024x487.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-1536x731.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45.png 1920w" alt="" width="1024" height="487" /></figure>
<h3 class="wp-block-heading">목요일 나스닥 100 주식 중 최악의 성과를 낸 10개 주식</h3>
<figure class="wp-block-table is-style-stripes">
<figure class="block core-blockblock core-block table">
<table class="block core-block table">
<tbody>
<tr>
<td>종목</td>
<td>1-Day %</td>
</tr>
<tr>
<td>룰루레몬 애틀라티카(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/lulu" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for LULU" data-google-interstitial="false">LULU</a>)</td>
<td>-9.03%</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/wbd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for WBD" data-google-interstitial="false">WBD</a>)</td>
<td>-5.73%</td>
</tr>
<tr>
<td>Arm 홀딩스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/arm" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ARM">ARM</a>)</td>
<td>-5.45%</td>
</tr>
<tr>
<td>허니웰 인터내셔널(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/hon" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HON">HON</a>)</td>
<td>-5.26%</td>
</tr>
<tr>
<td>어드밴스드 마이크로 디바이시스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/amd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for AMD">AMD</a>)</td>
<td>-4.36%</td>
</tr>
<tr>
<td>부킹 홀딩스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/bkng" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BKNG">BKNG</a>)</td>
<td>-3.86%</td>
</tr>
<tr>
<td>인튜이티브 서지컬(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/isrg" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ISRG">ISRG</a>)</td>
<td>-3.79%</td>
</tr>
<tr>
<td>온 세미컨덕터(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/on" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ON">ON</a>)</td>
<td>-3.67%</td>
</tr>
<tr>
<td>덱스콤(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/dxcm" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for DXCM">DXCM</a>)</td>
<td>-3.57%</td>
</tr>
<tr>
<td>퀄컴(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/qcom" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for QCOM">QCOM</a>)</td>
<td>-3.15%</td>
</tr>
<tr>
<td>알파벳(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/googl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for GOOGL">GOOGL</a>)</td>
<td>-3.07%</td>
</tr>
</tbody>
</table>
</figure>
</figure>
<h3 class="wp-block-heading">목요일 나스닥 100 주식 중 최고의 성과를 낸 5개 주식</h3>
<figure class="wp-block-table is-style-stripes">
<figure class="block core-blockblock core-block table">
<table class="block core-block table">
<tbody>
<tr>
<td>종목</td>
<td>1-Day %</td>
</tr>
<tr>
<td>아틀라시안(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/team" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TEAM">TEAM</a>)</td>
<td>6.34%</td>
</tr>
<tr>
<td>올드 도미니언 프레이트 라인(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/odfl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ODFL">ODFL</a>)</td>
<td>5.74%</td>
</tr>
<tr>
<td>몽고DB(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/mdb" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for MDB">MDB</a>)</td>
<td>4.83%</td>
</tr>
<tr>
<td>길리어드 사이언시스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/gild" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for GILD">GILD</a>)</td>
<td>4.12%</td>
</tr>
<tr>
<td>오릴리 오토모티브(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/orly" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ORLY">ORLY</a>)</td>
<td>4.09%</td>
</tr>
</tbody>
</table>
</figure>
</figure>
<h3></h3>
Photo via Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Gilead Sciences

뉴스

에 대한 최신 뉴스 Gilead Sciences (NASDAQ:GILD) 주식

수요일, 2월 12, 2025

화요일, 2월 11, 2025

월요일, 12월 23, 2024

화요일, 9월 03, 2024

목요일, 7월 25, 2024

일요일, 6월 23, 2024

토요일, 6월 22, 2024

화요일, 4월 09, 2024

월요일, 4월 01, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌